Table 1.
Patient Characteristics
| Characteristics | |
|---|---|
| Median age in years (range) | 75 (59-86) |
| Median initial PSA in ng/ml (range) | 21.70 (6.86-406.00) |
| Median prostate volume (ml) (range) | 34.79 (11.00-137.20) |
| Median PSAD (ng/ml2) (range) | 0.76 (0.10-16.69) |
| PIRADS, n (%) | |
| 4 | 17 (35.4) |
| 5 | 31 (64.5) |
| Hormonal treatment, n (%) | |
| No | 3 (6.3) |
| STADT | 5 (10.4) |
| LTADT | 40 (83.3) |
| Biopsy Gleason score, n (%) | |
| Up to 6 | 11 (22.9) |
| 7 | 11 (22.9) |
| 8-10 | 26 (54.2) |
| Clinical T stage, n (%) | |
| 2 | 18 (37.5) |
| 3 | 24 (50.0) |
| 4 | 6 (12.5) |
| D’Amico classification, n (%) | |
| Intermediate risk | 7 (14.6) |
| High risk | 41 (85.4) |
| Median, mean volume, ml (range) | |
| Whole Prostate Gland | 49.26 (25.53-181.83) |
| DIL | 3.67 (0.77-27.63) |
| Median total treatment time (months) (range) | 41 (32-52) |
Abbreviations: DIL, Dominant Intraprostatic Lesion; LTADT, Long-term Androgen Deprivation Therapy; PSA, Prostate Specific Antigen; PSAD: Prostate Specific Antigen Density; The prostate volume was measured on mpMRI; STADT, Short-term Androgen Deprivation Therapy.